Étiquette : Inflammatory diseases

BIOASTER

by jbertholdin Biotech, Pharma

BIOASTER

About the company

BIOASTER is the first Institute for Technological Innovation in Microbiology in France (Lyon and Paris, Pasteur Institute). They are Non-for-profit Technology Research Institute, active in the field of vaccine, immunomodulation, microbiota, anti-infectives, and IVD.
With BIOASTER, each project benefits from the right scientific and technology mix to address specific issues, quality in execution to meet high-standard requirements and case-by-case financial risk-sharing partnerships.
Their industrial partners come from a wide range of industries, including pharma, biotech, animal health, nutrition and diagnostics.

About the solution

Examples of partnership themes include for vaccine : Memory response /Longitudinal study, Efficacy, Memory response /Longitudinal study,correlate of protection, Breadth of protection, benchmarking with competitives vaccines, vaccine & adjuvant MOA, Exploratory research, preclinical & clinical biomarkers identification, system serology, immunometabolism (immunophenotyping at single cell), microbiota & immunity, host pathogen interaction.

Examples of partnership themes include for bioprocess- bioproduction & CMC: biomarkers identification for batch success/batch failure, digital tween & machine learning/deep Learning, method development & benchmarking, antigen characterization, potency assays development, Host Cell Proteins identification, CMC methods for in vitro mRNA production, mRNA formulation.

Website
Key information

– Therapeutic areas: Infectious & therapeutic vaccines, Immunology, Auto-immune diseases, Inflammatory diseases, Immuno-modulation, Microbiota, Antimicrobial, Antiviral, Ivd, Support to bioprocess optimization & bioproduction, Support to cmc

– Based in: Paris & Lyon (FRANCE)

– Employees: 51 – 200

– Created in: 2012

OSE IMMUNOTHERAPEUTICS

by jbertholdin Biotech, Pharma

OSE IMMUNOTHERAPEUTICS

About the company

OSE Immunotherapeutics is an integrated Clinical Stage biotech company mastering complex biology with regards to T-cells and myeloid cells, focused on developing first-in-class assets targeting immuno-oncology, Autoimmune and inflammatory diseases.

About the solution

OSE Immunotherapeutics has a dynamic partnership business model based on innovative products that generates non-dilutive revenues and finances R&D programs. These products have real blockbuster potential and give to OSE-Immunotherapeutics, an ability to conclude global agreements at different stages of their development with major pharmaceuticals players. We are interested to discuss potential collaborations. OSE-Immunotherapeutics actively seeks international partners for out-Licencing of compounds at all stages of clinical development of drug products.

Website
Key information

–  Therapeutic areas: Immuno-oncology, Autoimmune diseases, Inflammatory diseases

–  Based in: Headquarter : Nantes (FRANCE) Offices : Paris (FRANCE)

–  Employees: 51 – 200

–  Created in: 2012

TEMISIS

by jbertholdin Biotech, Pharma

TEMISIS

About the company

Temisis, a preclinical-stage biotechnology company, is developing innovative therapeutics for patients living with chronic inflammatory and auto-immune diseases, with a primary focus on psoriasis. Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications.

They believe that TEM2085, exhibiting significant efficacy in animal models of immuno-inflammatory diseases and resulting from our drug discovery platform, has the potential to show comparable efficacy to biologics which have demonstrated to date the greatest therapeutic benefit in this area. Temisis’ short-term goal is to move TEM2085 through final stages of preclinical development for clinical evaluation.

About the solution

Temisis’ lead drug candidate, TEM2085, is a first-in-class oral small molecule targeting NFKBIZ signaling, which is a key pro-inflammatory gene involved in the pathogenesis of a variety of immunological indications. In vitro, TEM2085 shows, at low concentrations, significant inhibition of NFKBIZ expression induced by IL-17/TNFα in keratinocytes. In vivo, TEM2085 has demonstrated in rodent models, at a lower dose, greater therapeutic benefit than the TYK2 inhibitor deucravacitinib against psoriasis and strong protection against ulcerative colitis. By targeting NFKBIZ signaling, TEM2085 and its analogues have the potential to address various immunological disorders.

Website
Key information

–  Therapeutic areas: Inflammatory diseases, Auto-immune diseases

–  Based in: Vandœuvre-lès-Nancy (FRANCE)

–  Employees: 1-10

–  Created in: 2017

AFFILOGIC

by jbertholdin Biotech, Pharma

AFFILOGIC

About the company

Affilogic is a private, French biotech company established in 2010. They are specialized in discovering and developing Nanofitins® through collaborations with worldwide industry leaders in the pharmaceutical sector.

About the solution

Nanofitins are small, hyperstable affinity proteins, which can be designed as targeted inhibitors, or as vectors for specific addressing of cells and tissues. Affilogic follows the science to any therapeutic area as long as an innovative Nanofitin-based biotherapy can make a difference to meet patients’ needs. Usual systemic routes can be travelled by Nanofitins®, but their intrinsic properties make them amenable to other routes, such as oral route and pulmonary delivery.

Website
Key information

–  Therapeutic areas: Infectiology, Oncology, CNS disorders, Inflammatory diseases

–  Based in: Nantes (FRANCE)

–  Employees: 11 -50

–  Created in: 2010